TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Need for mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in heat pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in von Frey pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in cold pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual bacterial growth prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Palatability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Precursor serrated polyp occurrence in TSAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BRAF mutation rate in CRCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-test performance retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Uncorrected Near Visual Acuity (UCNVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: matrix mineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: mineral crystallinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: collagen cross‐link ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: FIM motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of voxels with distortions of more than 2 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst phantom-measured residual system distortions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose differences between dCT and CT treatment plans in D50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients remaining seizure free throughout treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of minor side effects
Endpoint domain: Adverse events/effects
Primary endpoint: periprocedural stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Time taken to resume a regular diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total traction forces needed to displace ports
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of spontaneous port dislodgements
Endpoint domain: Adverse events/effects
Primary endpoint: Port-site bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of myocardial infarctions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major bleeding complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of profound thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global SOMA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Q-DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to recovery to a TOF ratio of ≥ 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD Rating Scale-IV scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions Severity Index ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrafraction and interfraction setup error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Behaviour change maintenance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: dyspnea relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breathing discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥III Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in CD3+/perforin+ cytotoxic T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease of EGFR-expressing cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Low-density lipoprotein cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Non-high-density lipoprotein cholesterol (non-HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total cholesterol (TC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: School-time SBP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 inhibitory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rMal d 1-induced oral symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rMal d 1-specific cutaneous reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG4/IgE ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalizations for diabetes-related complications
Endpoint domain: Mortality/survival
Primary endpoint: acute grade ≥ 2 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: clinically meaningful worsening in dyspnea QOL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relative aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage with an acceptable fitness level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: standardized uptake values of liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4/CD8 ratio ≥1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MTMR attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukopenia attacks
Endpoint domain: Adverse events/effects
Primary endpoint: rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: cytomegalovirus infections requiring full treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Tendency to form anal stricture
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of recurrent hemorrhoidal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 9-month survival rate
Endpoint domain: Mortality/survival
Primary endpoint: NEDA (No Evidence of Disease Activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postprandial FSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appendicular lean mass gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: minutes of moderate to vigorous physical activity (MVPA) per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: restoration of knee rotational and anterior laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: risk of chronicity of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary blood flow velocity (CTFC values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CK peak values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: WMSI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tube sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFPI concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: factor VII measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disability questionnaire score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberdeen back pain scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days off work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Days of reported fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new MRSA colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: sequential organ failure assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery criteria met
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Threshold change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iliac crest cancellous bone volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTH content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall severity of breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall unpleasantness of breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAV detectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSDE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Oral closure function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Swallowing function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: time to completion of the camera test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correct organ visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall time spent in the skill lab vs. operating room
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oswestry score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to work rate at three months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of excellent outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in women's mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of women with EPDS score of 13+
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life Impact of Refractive Correction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean near-final height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increment in height SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum budesonide plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to concentration maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVR decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cessation of pelvic muscle activity on EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in VDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loco-regional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annual rate of on-treatment moderate/severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: health status improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to phase II CR programme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: construct deformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fragment displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nimodipine AUC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: asthma responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: airway hyperresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decrease in circulating myeloid dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tinnitus Handicap Inventory (THI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS loudness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS annoyance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arrhythmic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Family adaptability
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Visibility of excretory ducts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean body weight change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of subjects losing at least 5% of initial body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived social support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Satisfaction with social life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Insulin resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median survival period
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (PFS) time
Endpoint domain: Mortality/survival
Primary endpoint: Retention percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CK activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fasted plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of symptoms in bipolar disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV end-systolic volume (LVESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV end-diastolic volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean pain VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of drusen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NASH resolution without fibrosis worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of smartphones
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timeliness of communication
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: User satisfaction with smartphone applications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to obtain R&D approval
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recurrent VT/VF events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: accumulation of T2 lesion load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BIS index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of awareness
Endpoint domain: Adverse events/effects
Primary endpoint: Average change in health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average change in vision-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prevalence of inadequate gestational weight gain (GWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weight gain by 36 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of overweight or obesity at 6 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance rate with trial protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of bacterial contamination
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of catheter-related bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: PAC to ARC ratio for diagnosis of aldosterone-secreting adrenal adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hyaluronic acid concentrations in cervical mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decisional conflict post‐diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Abundance of Bifidobacterium species in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein digestibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACQ change in high-reversibility subgroup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in lumbar range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sound localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful outcome (responders)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DWI T2‐shine through effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disc shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of IFNGS in blood and muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of ethinylestradiol and levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with glistenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean grade of glistenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic control of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: clinical and histologic parameters improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with day treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status